Change 5-day change 1-year change 3-year change Capi.($)
+5.60%-6.13% - - 303M
+0.99%+0.35%+4.91%+16.06% 48.7B
+3.71%+6.75%+459.45%+557.32% 42.05B
+2.70%+0.38%+34.49%+10.04% 38.26B
+5.60%+8.13%+16.67%+72.18% 37.5B
+2.21%+4.89%+17.24%+51.64% 31.44B
+2.23%+1.73% - - 16.47B
+0.97%+2.14%+37.25%+128.28% 16.33B
-0.11%+1.75%+8.05%+18.47% 13.98B
+0.75%+14.01%+77.94%+29.28% 12.68B
Average +2.50%+3.06%+82.00%+110.41% 28.6B
Weighted average by Cap. +2.58%+2.31%+98.60%+131.40%
Logo OvaScience Inc
Tempest Therapeutics, Inc.(Tempest), formerly Millendo Therapeutics, Inc., is a clinical-stage oncology company. The Company is focused on developing therapeutics that combine both targeted and immune-mediated mechanisms to treat a wide range of tumors. The Company's two clinical programs are TPST-1495 and TPST-1120. The Company's both TPST-1495 and TPST-1120 are advancing through Phase 1 studies designed to study both agents as monotherapies and in combination with other approved agents. Tempest is also developing an orally-available inhibitor of TREX-1 designed to activate cGAS/STING pathway, an innate immune response pathway important for the development of anti-tumor immunity.
Employees
-